Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Acquired hypogammaglobulinemia is common in chronic lymphocytic leukemia (CLL), non-
Hodgkin lymphoma (NHL), and multiple myeloma (MM). No previous systematic reviews …

Hematologic and oncologic patients with chemo-or immunotherapy-related
immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii …

Simple Summary Monoclonal antibodies represent a major therapeutic progress in multiple
myeloma during the last decade. The use of antibodies as well as antibody drug conjugates …

Immunoglobulin replacement and prophylactic antibiotics are commonly used to prevent
infections in patients with secondary hypogammaglobulinemia due to hematological …

The prognostic landscape of multiple myeloma (MM) has evolved significantly over the last
few decades. There are, however, few data measuring such improvement in real‐world …

In response to emerging discoveries, questions are mounting as to what factors are
responsible for the progression of plasma cell dyscrasias and what determines …

Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency
characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor …

Malignancies of the B‐lymphocyte lineage are among the most diagnosed haematological
malignancies in clinical practice. In our community, multiple myeloma (MM) and its precursor …

The recent therapeutic progress in multiple myeloma (MM) has led to the introduction of
novel and highly potent drug classes. Daratumumab was the first CD38-targeting antibody …